I would like to thank Dr Marlicz and colleagues for their interesting comment about the current use of rifaximin in the management of diverticulosis and diverticular disease.1 In particular, all their ...

"In the short-term, the most immediate threat to our community-based mission is a bureaucratic delay in Washington, D.C.," writes Stephen Gray in a Guest Commentary. "And it’s costing us between $14 ...